1 The influence of food on the absorption of frusemide and bumetanide was compared in two separate randomized crossover studies. 2 On three separate occasions frusemide 40 mg was administered to eight healthy male volunteers intravenously, orally in the fasting state and orally after a standard breakfast. Blood and urine were collected at intervals over 8 h and urine alone for a further 16 h. The study was then repeated in nine healthy volunteers using intravenous and oral bumetanide 2 mg. 3 Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35±0.49 to 0.51±0.19 mg l−1 ( 95% confidence intervals (95% CI)= 1.39 to 2.28 mg l−1) and delayed the time to peak concentration from 0.69±0.21 to 1.91±0.93 h (95% CI=0.41 to 2.03 h). The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6±10.6 to 43.2±16.8%; 95% CI=13.5 to 51.4%). 4 With bumetanide, the meal also significantly reduced the peak concentration from 0.097±0.015 to 0.036±0.012 mg l−1 (95% CI=0.048 to 0.073 mg l−1) and delayed the time to peak from 0.53±0.08 to 1.36±0.72 h ( 95% CI=0.23 to 1.44 h). However, food had no statistically significant effect on the bioavailability and urinary recovery of bumetanide. 5 In this study, the absorption of bumetanide was affected less than frusemide by food.
Introduction
bumetanide is affected by food. It was reported in an abstract that food delayed the response to oral bumetanide in healthy volunteers but no pharmacokinetic data Frusemide and bumetanide are loop diuretics commonly used in the treatment of oedematous states associated were presented [ 11] . The present studies were therefore conducted to with cardiac, renal and hepatic disease [1, 2] . Frusemide is absorbed incompletely from the gastrointestinal tract obtain additional information on the effects of food on frusemide and bumetanide absorption in man. and there is considerable intra-and inter-individual variability in its bioavailability [3, 4 ] . In healthy volunteers, food had variable effects on its absorption. Kelly et al. [5 ] and Hammarlund et al. [6] found that food had no statistically significant influence on the Methods extent of absorption of frusemide although Hammarlund et al. [6] reported that it delayed absorption. In Subjects contrast, Beermann & Midskov [7 ] observed a 30% reduction in the bioavailability of frusemide given as a Eight healthy male volunteers, aged 21 to 38 years (28±5 (s.d.) years) and weighing 51 to 82 kg (70±10 kg ), tablet with food.
Bumetanide is 40-60 times more potent as a diuretic participated in the first, randomized, crossover study with frusemide. In the second study with bumetanide, than frusemide on a weight basis and it has a greater oral bioavailability (approximately 80% vs 40%) [8] [9] [10] .
nine healthy male volunteers (aged 27±5 years and weighing 67±7 kg) took part. Three of these subjects However it is not known whether the absorption of Correspondence: Dr J. L. McCrindle, Axess Limited, Axess House, Forest Road, Kew, UK had previously participated in the frusemide study. All (Division of Millipore, Milford, MA, U.S.A.). Separation was carried out using a Radial Compression reverse the volunteers were healthy according to medical history, clinical examination, haematological and biochemical phase column (Waters Novapak C 18 ODS, 4 mm). Frusemide and the internal standard, desmethylnaptests. They gave written informed consent and the study was approved by the Lothian Healthy Volunteer roxen, were measured using a luminescence spectrophotometer (Perkin Elmer Ltd, Beaconsfield, Bucks, U.K.) Research Ethics Subcommittee. The volunteers avoided taking any other medication for 1 week prior to and with excitation and emission wavelengths of 275 and 400 nm, respectively. The sensitivity of the assay was throughout the studies. They abstained from alcohol for 24 h and refrained from food and caffeine containing 50 mg l−1. Bumetanide in plasma was analysed using h.p.l.c. with fluorescence detection as described by Wells drinks from 22.00 h the evening before each study day.
et al. [13 ] . A Waters 5 mm 'Resolve' C 18 column was used. Piretanide was used as the internal standard and the excitation and emission wavelengths were set at 228 Protocol and 418 nm, respectively. The limit of detection of the assay was 2.5 mg l−1. For both frusemide and bumetanIn the first study with frusemide, each volunteer attended at 08.00 h following an overnight fast on three separate ide, urine samples containing the internal standards were injected directly onto the h.p.l.c. column. Frusemide occasions, at least 1 week apart. Intravenous cannulae were inserted into each forearm, one for drug adminisand bumetanide concentrations were determined by comparing peak area ratios of drug to internal standard tration and fluid replacement, and the other for collection of blood samples. After emptying their with a standard calibration curve. bladders, the volunteers received either: 1 Intravenous frusemide 40 mg infused at constant rate over 5 min Pharmacokinetic analysis 2 Oral frusemide solution 40 mg 3 Oral frusemide solution 40 mg immediately after Noncompartmental analysis was used following oral administration with food because the data could not be breakfast. The frusemide was given as 10 mg ml−1 LasixA for fitted to a conventional model. The area under the plasma concentration versus time curve up to 8 h injection. Oral frusemide was taken in 100 ml of orange squash (Kia-Ora), washed down with a further 100 ml (AUC(0,8 h) was calculated by the trapezoidal rule and the area beyond the last measured concentration to of water. When taken with food, the drug was ingested immediately after a standard breakfast consisting of infinity was estimated as the concentration divided by the intravenous elimination rate constant. It was orange juice (200 ml ), scrambled eggs, cornflakes with milk and two slices of toast with butter and jam. The assumed that the disposition of the drugs would be similar after intravenous and oral administration. The volunteers remained supine throughout each study (except when passing urine) and they had nothing to bioavailabilities of oral frusemide and bumetanide were calculated as the ratios of the respective AUCs after eat or drink until 5 h after dosing, when a light lunch was provided. To replace fluid losses, 500 ml of 0.9% oral and intravenous administration. sodium chloride solution was given intravenously over the first hour and subsequently, hourly urine volumes were replaced by the same volume of intravenous 5% Statistical analysis dextrose.
Venous blood was collected into lithium heparin tubes All values are expressed as means±s.d. Statistical differences between doses were determined using analysis before, and at 3, 5, 10, 15, 30, 45, 60, 90, 120 min, and hourly for the next 6 h after the intravenous dose.
of variance and P values of <0.05 were considered significant. Following oral doses samples were taken at 0, 10, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180 min, and hourly for the next 5 h. The plasma was separated and stored at −20°C. Urine was collected at 1, 2, 3, 4, 5, 6 and 8 h after dosing and from 8-24 h. Urine volumes were Results recorded and aliquots stored at −20°C.
In the second study, bumetanide 2 mg solution was Frusemide administered as 0.5 mg ml−1 BurinexA injection intravenously and orally with and without breakfast exactly Mean plasma concentrations for oral frusemide given with and without food are shown in Figure 1 . The as described for frusemide. A similar schedule was used for blood and urine sampling.
presence of food dramatically changed the shape of the curve. given with and without food were 74.8±15.5 and and without (') food in eight healthy volunteers.
83.7±12.4% (95% CI=−1.82 to 19.5%). The difference was not statistically significant ( Table 1 ). The mean 24 h urinary recovery of bumetanide taken with and without fasting compared with 1.95±0.72 mg l−1 h with food food averaged 50.1±15.6 and 59.7±8.4% (95% CI= (95% CI=0.59 to 2.59 mg l−1 h; P<0.01) ( Table 1) . −1.26 to 20.5%), respectively ( Figure 2 ) . The difference The bioavailability of frusemide was significantly was not statistically significant. The corresponding reduced from 75.6±10.6% fasting to 43.2±16.8% recovery after intravenous bumetanide was 71.4±8.5%. when administered with food (95% CI=13.5 to 51.4%; P<0.01) ( Table 1 ). The renal elimination of unchanged frusemide in the 24 h following intravenous and oral administration is shown in Figure 2 . Food significantly Discussion decreased the excretion of frusemide (29.6±6.1%) compared with fasting (45.4±7.9%; 95% CI=10.5 to Food had a dramatic effect on the oral absorption of 20.5%; P<0.001). The corresponding recovery after frusemide producing a significant reduction in C max , a intravenous frusemide was 67.2±3.4%. delay in t max and a 30% reduction in bioavailability. These results contrast with those obtained by Kelly et al. following oral administration of 2 mg in solution with (%) and without (') food in nine healthy volunteers. ***P<0.001, compared with oral with food. given with and without food. However, the study by reduced.
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